BAJAJ BROKING
Suven Pharmaceuticals has officially merged with Cohance Lifesciences and will now operate as Cohance Lifesciences Limited. The final regulatory nod enables full integration from 1 May 2025.
Suven Pharmaceuticals has completed its merger with Cohance Lifesciences and will now operate under the name Cohance Lifesciences Limited. The final approval from the Department of Pharmaceuticals (DoP) has allowed the company to implement the Scheme of Amalgamation. This strategic move marks a significant transformation in Suven’s identity and capabilities as it evolves into a broader contract development and manufacturing organisation (CDMO) platform.
Also read: JBM Auto Aims Rs.6,500 Crore Revenue by FY26, Rides EV Growth Wave
Merger between Suven Pharma and Cohance Lifesciences effective from 1 May 2025.
New entity to operate under the name Cohance Lifesciences Limited.
Final approval secured from the Department of Pharmaceuticals.
Record date for share allotment set as 8 May 2025.
Suven Pharma share price performance remains in focus post-merger.
Also read: Newgen Software Targets 20% Growth, US Market to Lead Expansion
With the merger in effect, the company is undergoing operational and structural integration to ensure a seamless transition. The amalgamated entity is expected to strengthen its focus on high-growth CDMO modalities, including antibody-drug conjugates (ADCs) and oligonucleotides, aligning with global demand for complex drug development capabilities.
The merger had previously received shareholder approval and a green light from the National Company Law Tribunal (NCLT), Mumbai Bench. The Board has also approved 8 May 2025 as the record date to determine eligible shareholders for share exchange in line with the agreed ratio under the Scheme of Amalgamation.
Event | Details |
Merger Effective Date | 1 May 2025 |
New Entity Name | Cohance Lifesciences Limited |
Final Approval Received From | Department of Pharmaceuticals (DoP) |
Record Date for Shareholders | 8 May 2025 |
Strategic Focus Areas | ADCs, Oligonucleotides, CDMO |
As operations consolidate under the new name, Suven Pharma share price could reflect future expectations around synergy benefits, global expansion, and innovation-driven growth. Investors and stakeholders are closely watching how the rebranded Cohance Lifesciences delivers on its broader strategic objectives. With enhanced capabilities, the entity aims to compete more effectively in the global CDMO market.
Also read: Alembic Pharma Eyes US Growth, Margins in Animal Health Business
Share this article:
Disclaimer :
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading